Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

CervoMed (CRVO) Shares Issued (2023 - 2025)

CervoMed (CRVO) has disclosed Shares Issued for 7 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • Quarterly Shares Issued rose 35332.38% to $4.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 1079.93% year-over-year, with the annual reading at $46.4 million for FY2024, 5628.22% up from the prior year.
  • Shares Issued hit $4.7 million in Q3 2025 for CervoMed, roughly flat from $4.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $4.7 million in Q2 2025 to a low of -$13340.0 in Q3 2024.
  • Historically, Shares Issued has averaged $2.5 million across 3 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Shares Issued: plummeted 101.65% in 2024 and later surged 35332.38% in 2025.
  • Year by year, Shares Issued stood at $810000.0 in 2023, then tumbled by 101.65% to -$13340.0 in 2024, then soared by 35332.38% to $4.7 million in 2025.
  • Business Quant data shows Shares Issued for CRVO at $4.7 million in Q3 2025, $4.7 million in Q2 2025, and -$13340.0 in Q3 2024.